These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 35971888)

  • 21. AGA Clinical Practice Update on the Diagnosis and Management of Extraesophageal Gastroesophageal Reflux Disease: Expert Review.
    Chen JW; Vela MF; Peterson KA; Carlson DA
    Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1414-1421.e3. PubMed ID: 37061897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
    Ribolsi M; Cicala M; Zentilin P; Neri M; Mauro A; Efthymakis K; Petitti T; Savarino V; Penagini R
    Aliment Pharmacol Ther; 2018 Nov; 48(10):1074-1081. PubMed ID: 30294924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical utility of salivary pepsin measurement in patients with proton pump inhibitor-refractory gastroesophageal reflux disease symptoms: a prospective comparative study.
    Matsumura T; Arai M; Suzuki T; Hoppo T; Seki Y; Kasamatsu S; Ishigami H; Ishikawa K; Okimoto K; Akizue N; Maruoka D; Nakagawa T; Odaka T; Okamoto Y; Kato N
    Esophagus; 2020 Jul; 17(3):339-347. PubMed ID: 31982992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group.
    Roman S; Gyawali CP; Savarino E; Yadlapati R; Zerbib F; Wu J; Vela M; Tutuian R; Tatum R; Sifrim D; Keller J; Fox M; Pandolfino JE; Bredenoord AJ;
    Neurogastroenterol Motil; 2017 Oct; 29(10):1-15. PubMed ID: 28370768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon Consensus.
    Ribolsi M; Frazzoni M; Marabotto E; De Carlo G; Ziola S; Maniero D; Balestrieri P; Cicala M; Savarino E
    Aliment Pharmacol Ther; 2021 Aug; 54(4):412-418. PubMed ID: 34181753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Majority of symptoms in esophageal reflux PPI non-responders are not related to reflux.
    Roman S; Keefer L; Imam H; Korrapati P; Mogni B; Eident K; Friesen L; Kahrilas PJ; Martinovich Z; Pandolfino JE
    Neurogastroenterol Motil; 2015 Nov; 27(11):1667-74. PubMed ID: 26337396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is the proton pump inhibitor test helpful in patients with laryngeal symptoms?
    Kim JH; Sung IK; Hong SN; Lee SY; Park HS; Shim CS
    Dig Dis Sci; 2013 Jun; 58(6):1663-7. PubMed ID: 23443492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tailored therapy for the refractory GERD patients by combined multichannel intraluminal impedance-pH monitoring.
    Xiao Y; Liang M; Peng S; Zhang N; Chen M
    J Gastroenterol Hepatol; 2016 Feb; 31(2):350-4. PubMed ID: 26202002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review article: modern technology in the diagnosis of gastro-oesophageal reflux disease--Bilitec, intraluminal impedance and Bravo capsule pH monitoring.
    Hirano I
    Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():12-24. PubMed ID: 16483266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
    Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
    Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease.
    Bytzer P; Jones R; Vakil N; Junghard O; Lind T; Wernersson B; Dent J
    Clin Gastroenterol Hepatol; 2012 Dec; 10(12):1360-6. PubMed ID: 22813439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical trial: a controlled trial of baclofen add-on therapy in PPI-refractory gastro-oesophageal reflux symptoms.
    Pauwels A; Raymenants K; Geeraerts A; Boecxstaens V; Masuy I; Broers C; Vanuytsel T; Tack J
    Aliment Pharmacol Ther; 2022 Jul; 56(2):231-239. PubMed ID: 35665521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management options for patients with GERD and persistent symptoms on proton pump inhibitors: recommendations from an expert panel.
    Yadlapati R; Vaezi MF; Vela MF; Spechler SJ; Shaheen NJ; Richter J; Lacy BE; Katzka D; Katz PO; Kahrilas PJ; Gyawali PC; Gerson L; Fass R; Castell DO; Craft J; Hillman L; Pandolfino JE
    Am J Gastroenterol; 2018 Jul; 113(7):980-986. PubMed ID: 29686276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postreflux swallow-induced peristaltic wave index and nocturnal baseline impedance can link PPI-responsive heartburn to reflux better than acid exposure time.
    Frazzoni L; Frazzoni M; de Bortoli N; Tolone S; Furnari M; Martinucci I; Bertani H; Marchi S; Conigliaro R; Fuccio L; Savarino V; Savarino E
    Neurogastroenterol Motil; 2017 Nov; 29(11):. PubMed ID: 28543861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ESNM/ANMS consensus paper: Diagnosis and management of refractory gastro-esophageal reflux disease.
    Zerbib F; Bredenoord AJ; Fass R; Kahrilas PJ; Roman S; Savarino E; Sifrim D; Vaezi M; Yadlapati R; Gyawali CP
    Neurogastroenterol Motil; 2021 Apr; 33(4):e14075. PubMed ID: 33368919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective validation of reflux monitoring by impedance-pH in predicting PPI response in typical GERD.
    Ribolsi M; Savarino E; Frazzoni M; Cicala M
    Dig Liver Dis; 2023 Jun; 55(6):721-726. PubMed ID: 36572569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of Esophageal pH Monitoring to Minimize Proton-Pump Inhibitor Utilization in Patients with Gastroesophageal Reflux Symptoms.
    Triadafilopoulos G; Zikos T; Regalia K; Sonu I; Fernandez-Becker NQ; Nguyen L; Nandwani MCR; Clarke JO
    Dig Dis Sci; 2018 Oct; 63(10):2673-2680. PubMed ID: 29959725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged Wireless pH Monitoring in Patients With Persistent Reflux Symptoms Despite Proton Pump Inhibitor Therapy.
    Hasak S; Yadlapati R; Altayar O; Sweis R; Tucker E; Knowles K; Fox M; Pandolfino J; Gyawali CP
    Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2912-2919. PubMed ID: 32007543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ambulatory pH-Impedance Findings Confirm That Grade B Esophagitis Provides Objective Diagnosis of Gastroesophageal Reflux Disease.
    Visaggi P; Del Corso G; Gyawali CP; Ghisa M; Baiano Svizzero F; Stefani Donati D; Venturini A; Savarino V; Penagini R; Zeki S; Bellini M; Savarino EV; de Bortoli N
    Am J Gastroenterol; 2023 May; 118(5):794-801. PubMed ID: 36633477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease.
    Cicala M; Emerenziani S; Guarino MP; Ribolsi M
    World J Gastroenterol; 2013 Oct; 19(39):6529-35. PubMed ID: 24151377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.